BPC-157
The connective-tissue research workhorse. Pure U.S. Peptides publishes a per-batch HPLC certificate of analysis on the product page.
View product →Paradigm Peptides Shut Down: The Verified Facts
Unlike most vendor closures, this one has a public court record. Below is what the U.S. Department of Justice has actually published, what the site does today, and — if you bought from them between 2019 and 2024 — a number worth calling.
Domain status independently checked and page reviewed July 31, 2026.
What paradigmpeptides.com serves today
Nothing usable. We requested the domain repeatedly on July 31, 2026. It still resolves through its CDN, but nothing is served from behind it — five consecutive checks returned 522 Connection timed out, and an earlier attempt returned a 403. Either way it is a CDN error page, not a storefront and not a closure message. In plain terms: the domain has not been released, but there is no working site behind it, and the company left no notice explaining anything to its former customers.
This matters for one practical reason. If you land on something that looks like a working Paradigm Peptides storefront, it is not being served from this domain, and you should treat it with suspicion.
What the public record says
The U.S. Attorney's Office for the Northern District of Indiana maintains a case page for this matter. According to that page, Matthew Kawa was the owner of the internet business known as “Paradigm Peptides” or “Paradigm R.E. LLC,” which operated paradigmpeptides.com and shipped from Michigan City, Indiana. Jennifer Stechkober is described as Kawa's sister and an employee of the business — not, as is often reported elsewhere, a co-owner.
The DOJ page states: “On December 10, 2025, both defendants, Matthew Kawa and Jennifer Stechkober, entered a plea of guilty to the charge(s) in the Information.” On the underlying conduct, it says federal investigators determined that many products advertised and sold as containing SARMs in fact contained testosterone, a controlled substance, and that the SARM, hCG and peptide products sold were new drugs unapproved by the FDA.
On sentencing, CBS News reported that both were sentenced on July 30, 2026 by Judge Cristal Brisco in South Bend. Kawa received 70 months — just under six years — in federal prison and agreed to forfeit $5 million in proceeds from the business. Stechkober received 16 months.
One point of sequence is worth stating plainly, because it is routinely reported backwards: Paradigm stopped selling around March 2024, roughly 21 months before either defendant entered a plea. The business did not close in response to being charged. The DOJ's own page points the same way — the purchase window it names when addressing potential victims ends in March 2024.
We limit this page to those sources. We do not characterise what the sentences mean for anyone's future, and we do not speculate about matters the record does not cover. In particular, no injunction barring anyone from this industry appears anywhere in the public record, and we make no such claim.
If you bought from Paradigm Peptides between April 2019 and March 2024
The DOJ case page addresses former customers directly. It states that if you purchased any products from Paradigm Peptides between April 2019 and March 2024, you may or may not be a victim in the case, and asks anyone who believes they are to call 219-937-5500 and ask for the Victim Witness Specialist. That is the government's own line, not ours — we have no involvement in the case and cannot advise you on it.
For the official source, see the U.S. Department of Justice case page for the Northern District of Indiana. For a fuller timeline see What Happened to Paradigm Peptides, and for supplier options see Paradigm Peptides Alternative.
One caution worth stating plainly: a well-known brand that stops trading is an obvious target for impersonation. If you receive an email or advertisement announcing that Paradigm Peptides has reopened, do not enter payment details without independent verification.
Common swaps for former Paradigm researchers
TB-500
Actin-binding research peptide, commonly paired with BPC-157. U.S.-fulfilled, with a public per-batch COA.
View product →Ipamorelin
A selective ghrelin-receptor research compound, with HPLC verification published per lot.
View product →Selank
A synthetic tuftsin-analog research peptide, with a public per-batch COA.
View product →Semax
An ACTH(4-10)-fragment research peptide, with a public per-batch COA.
View product →What to check in a replacement supplier
The documented allegation in this case was that what was on the label did not match what was in the vial. That makes independent verification the whole ballgame, so it is worth being specific about what to ask for:
- A lot-specific certificate of analysis. Published on the product page, from an independent lab, matching the batch you would actually be shipped — not a representative COA from a different lot.
- U.S.-based fulfilment. A domestic warehouse and no import step.
- A research-only catalog. Compounds labelled and sold for laboratory research, without therapeutic marketing attached.
- Ordinary payment methods. Card checkout alongside other options, rather than crypto-only — which also preserves your dispute rights if something goes wrong.
Pure U.S. Peptides — research-only, U.S.-fulfilled
HPLC-verified research compounds with public per-batch COAs. Use code PARADIGMSWITCH25 for 20% off your first order.
Browse the catalog →Research Use Only. All compounds sold by Pure U.S. Peptides are intended exclusively for in-vitro research and laboratory use by qualified investigators. They are not intended for human or veterinary consumption.
Educational content. This page reports facts published by the U.S. Department of Justice for the Northern District of Indiana and by CBS News, each attributed above. It is a summary of the public record, not legal advice, and it makes no allegation beyond what those sources state. Pure U.S. Peptides has no business relationship with Paradigm Peptides, Matthew Kawa, or Jennifer Stechkober, and no involvement in the underlying federal case. The DOJ citation is for context only and does not imply DOJ endorsement of Pure U.S. Peptides. If you believe something on this page is inaccurate, contact us and we will correct it.